Compare Charles River Laboratories Intl. Inc (CRL) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Impinj Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231.94 (market cap $11.14B), while Impinj Inc trades at $145.13 (market cap $4.40B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.5× Impinj Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.
| CRL | PI | |
|---|---|---|
Market Cap | $11.14B | $4.40B |
Sector | Health | Technology |
52-Week High | $233.60 | $241.91 |
52-Week Low | $145.57 | $91.34 |
Enterprise Value | $14.00B | $4.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Impinj (PI) trades at $146.02, up 1.38% with a bullish technical signal supported by moving averages. The company shows mixed fundamentals with a negative net income margin of -7.66% but beat Q1 2026 EPS estimates. Revenue remains stable at $361M annually, though profitability challenges persist with elevated valuation ratios like P/S of 11.89. Analyst consensus is strongly bullish with 73% buy ratings and a $167.50 price target.
Outlook remains cautiously optimistic given strong analyst support and technical momentum, but investors face risks from insider selling and ongoing profitability challenges. The stock offers potential upside to consensus targets if execution improves, though negative margins and competitive pressures warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
